NASDAQ:GHDX - Genomic Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$65.97 -3.37 (-4.86 %)
(As of 12/18/2018 08:00 AM ET)
Previous Close$69.34
Today's Range$65.11 - $69.53
52-Week Range$30.04 - $92.18
Volume615,600 shs
Average Volume420,328 shs
Market Capitalization$2.50 billion
P/E Ratio84.56
Dividend YieldN/A
Beta0.39
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GHDX
Previous Symbol
CUSIP37244C10
Phone650-556-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio4.89
Quick Ratio4.89

Price-To-Earnings

Trailing P/E Ratio84.56
Forward P/E Ratio62.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$340.75 million
Price / Sales6.99
Cash Flow$0.3319 per share
Price / Cash Flow198.78
Book Value$5.41 per share
Price / Book12.19

Profitability

EPS (Most Recent Fiscal Year)$0.01
Net Income$-3,850,000.00
Net Margins4.95%
Return on Equity14.05%
Return on Assets11.57%

Miscellaneous

Employees863
Outstanding Shares36,120,000
Market Cap$2.50 billion
OptionableOptionable

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) announced its quarterly earnings results on Tuesday, November, 6th. The medical research company reported $0.35 EPS for the quarter, beating analysts' consensus estimates of $0.07 by $0.28. The medical research company earned $101.30 million during the quarter, compared to analyst estimates of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The firm's revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) earnings per share. View Genomic Health's Earnings History.

When is Genomic Health's next earnings date?

Genomic Health is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Genomic Health.

What guidance has Genomic Health issued on next quarter's earnings?

Genomic Health updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $1.03-$1.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.53. The company issued revenue guidance of $389-$391 million, compared to the consensus revenue estimate of $380.74 million.Genomic Health also updated its FY 2018 guidance to $1.03-1.08 EPS.

What price target have analysts set for GHDX?

9 Wall Street analysts have issued 1 year price targets for Genomic Health's stock. Their forecasts range from $28.00 to $82.00. On average, they anticipate Genomic Health's stock price to reach $48.1429 in the next twelve months. This suggests that the stock has a possible downside of 27.0%. View Analyst Price Targets for Genomic Health.

What is the consensus analysts' recommendation for Genomic Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health.

Has Genomic Health been receiving favorable news coverage?

Media stories about GHDX stock have been trending negative on Tuesday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genomic Health earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 59)
  • Dr. Steven Shak, Co-Founder, Chief Scientific Officer & Chief Medical Officer (Age 67)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 62)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 59)
  • Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 55)

Who are Genomic Health's major shareholders?

Genomic Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc (5.96%), Vanguard Group Inc. (5.96%), BlackRock Inc. (5.68%), Renaissance Technologies LLC (4.97%), Acadian Asset Management LLC (1.47%) and Loomis Sayles & Co. L P (1.35%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Which institutional investors are selling Genomic Health stock?

GHDX stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Candriam Luxembourg S.C.A., EAM Investors LLC, University of Notre Dame DU Lac, GSA Capital Partners LLP, BlueMountain Capital Management LLC, Aurora Investment Counsel and Bank of New York Mellon Corp. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Which institutional investors are buying Genomic Health stock?

GHDX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc, Vanguard Group Inc., Acadian Asset Management LLC, Federated Investors Inc. PA, Clearbridge Investments LLC, Deutsche Bank AG and FMR LLC. View Insider Buying and Selling for Genomic Health.

How do I buy shares of Genomic Health?

Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $65.97.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $2.50 billion and generates $340.75 million in revenue each year. The medical research company earns $-3,850,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Genomic Health employs 863 workers across the globe.

What is Genomic Health's official website?

The official website for Genomic Health is http://www.genomichealth.com.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]


MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  316 (Vote Underperform)
Total Votes:  571
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel